drugset / Trial / NCT00817635
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
Phase 2
Completed
155 enrolled
Novartis
Great Lakes Drug Development, Inc. · collabIntegrium · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
Timeline
- Start
- 2008-12-22
- Primary completion
- 2009-10-13
- Completion
- 2009-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eplerenone | Unknown | 50 mg | Oral |
| Subject | osilodrostat | Small molecule | 0.25 mg | Oral |
| Subject | osilodrostat | Small molecule | 1 mg | Oral |